Duopharma Biotech Bhd MYX:DPHARMA:
Q1 2026 PROFIT ATTRIBUTABLE TO EQUITY HOLDERS 30.71 MILLION RGT VERSUS 25.64 MILLION RGT YEAR AGO
Q1 2026 REVENUE 247.88 MILLION RGT VERSUS 262.74 MILLION RGT YEAR AGO
Duopharma Biotech Reports Quarterly Profit Attributable Of 30.71 Million RGT
Earlier from Duopharma Biotech Bhd
- Duopharma Biotech Says Government Accepts Tender Offer For Supply Of Insulin Injection By Unit
- Duopharma Biotech Appoints Puan Rohayu Rosnani Binti Mohd Adanan As CFO
- Duopharma Biotech Posts Qtrly Revenue 222.5 Million RGT